English 網站地圖 臺大首頁 中文 Site Map NTU SDG
國立臺灣大學生物資源暨農學院網站LOGO
亮點報導
Highlights

中草藥缺藥嚴重 形同另類「國安危機」

臺大與國家中醫藥研究所合作發展本土中草藥

 

中草藥缺藥問題嚴重被認為是「國安危機」,臺灣大學今天(19日)與衛福部國家中醫藥研究所簽署合作備忘錄,共同振興本土中草藥的栽培和利用,除了解決本土中草藥缺乏問題,甚至期盼成為全球中草藥供應的領頭羊。

 

由於化學合成藥劑如抗生素之大量使用,以及對於疾病之治療所引發之副作用,使得天然的藥用植物再度受到世人研究與重視,尤其近年來生活水準提高,一般民眾也逐漸注重身體之保健與養生,使得保健食品的市場活絡及研究藥用植物之風氣日益盛行,「中草藥」再度引發世人的普遍重視。

 

國家中醫藥研究所是我國唯一的國家級中醫藥研究機構,長期負責中醫藥研究、實驗及發展等事宜,是台灣最具規模的中草藥研究重鎮。近年由於Covid19爆發,國家中醫藥研究所開發的「台灣清冠一號」,經由基原鑑定與臨床測試而成的強化配方,能有效的緩解輕症新型冠狀病毒,不僅更打響國立中醫藥研究所名號,也間接大幅提升國人看中醫的意願。

 

國家中醫藥研究所所長蘇奕彰表示,全球的中草藥需求近年來增加兩成,而台灣的中醫師在疫情期間下星期要藥什麼藥都不知道,只能有什藥就用什麼藥,缺藥問題相當嚴重,可說是另類的「國安危機」。

 

蘇奕彰表示,未來全球中草藥需求只會增加,不會減少,進口成本只會增多,不會減少,而目前台灣的中草藥幾乎都靠進口,包括九成從大陸進口,其餘從東南亞、西亞進口;未來與臺大合作可突破學術上的基礎與發展,而且解決種植與使用的連結。

 

代表臺灣大學簽署合作備忘錄的臺大生物資源暨農學院院長林裕彬表示,生農學院具有完整的作物栽培及應用科系,包括農藝、園藝、農業化學、植物微生物、食品科技、生物技術等科系,並且有不同環境條件、不同海拔的栽培試驗研究場域,包括平地農場、雲林校區、實驗林、梅峰農場等,可提供完整及全面的技術與場域進行中草藥的栽培及研究。

 

林裕彬表示,近年中草藥需求激增,加上進口品項逐漸緊縮,為避免未來貨源不足,有必要建立本土中草藥栽培和繁殖方法,找出適合台灣環境栽培的品系,並將本土中草藥栽培標準化。

 

未來雙方可合作方向包括:建立藥食兩用中草藥示範園區,評估並鑑定適合台灣生長的中草藥,生產進口逐漸受限的中草藥、評估中草藥應用於動物保健,高活性成分的中草藥育種等。透過此次簽署合作意向書,將可推升雙方合作,一起為振興台灣中草藥努力。

臺大與衛福部國家中醫藥研究所簽署合作備忘錄,發展本土中草藥。(左:臺大生物資源暨農學院院長林裕彬、右:國家中醫藥研究所所長蘇奕彰)

 

NTU and the National Research Institute of Chinese Medicine Sign Agreement on joint development of the cultivation and utilization of Chinese herbal medicine

 

On December 19, Yu-Pin Lin, Dean of Bioresources and Agriculture at National Taiwan University (NTU), signed an agreement with the National Research Institute of Chinese Medicine (NRICM) to jointly develop the cultivation and utilization of Chinese herbal medicine.

 

Su Yi-Chang, Director of NRICM, along with Managing Deputy Director Chiou Wen-Fei, Chief of the Division of Chinese Materia Medica Development Lin Lie-Chwen, and Principal Investigators Liaw Chia-Chin and Chen Chang-Chang from NRICM, attended the event. The two sides discussed future collaboration.

 

The College of Bioresources and Agriculture at NTU encompasses a comprehensive range of departments dedicated to crop cultivation and applied sciences, such as agronomy, horticulture, agricultural chemistry, plant and microbiology, food technology, biotechnology, and more. It boasts cultivation experimental research sites with varying environmental conditions and altitudes, including the main campus farms, Yunlin Campus, Experimental Forest, Highland Experimental Farm, etc. These facilities provide a complete and comprehensive set of technologies and fields for the cultivation and research of Chinese herbal medicine.

 

NRICM is the only and largest national research institution for traditional Chinese medicine in Taiwan. The 'NRICM101 (also known as Taiwan Qingguan No. 1),' developed by the NRICM, is an enhanced formula that has undergone genetic identification and clinical testing. It can effectively alleviate mild Covid-19. This not only enhances the reputation of the NRICM but also strengthens people’s trust in traditional Chinese medicine.

 

In recent years, there has been a surge in demand for Chinese herbal medicines, resulting in a gradual reduction in the number of imported items. To address the risk of insufficient supply in the future, it is essential to establish local Chinese herbal medicine cultivation and propagation methods. This involves identifying strains suitable for cultivation in Taiwan's environment and standardizing the cultivation of local Chinese herbal medicines.

 

Through the signing of the MOU for cooperation, the two parties will be able to promote cooperation and work together to strengthen the cultivation and utilization of Chinese herbal medicine in Taiwan. Possible future directions for bilateral cooperation include establishing a Chinese herbal medicine demonstration park for both medicinal and food uses, developing cultivation and propagation methods for major Chinese herbal medicines, evaluating and identifying Chinese herbal medicines suitable for growing in Taiwan, producing Chinese herbal medicines whose imports are gradually restricted, assessing the application of Chinese herbal medicines in animal health and disease prevention, and breeding Chinese herbal medicines with high active ingredients.

臺大與衛福部國家中醫藥研究所簽署合作備忘錄,發展本土中草藥。(左:臺大生物資源暨農學院院長林裕彬、右:國家中醫藥研究所所長蘇奕彰)

 

回上頁